We conducted a randomized , double-blind , active-controlled , phase @ study involving @ patients with relapsing-remitting multiple sclerosis to compare daclizumab HYP , administered subcutaneously at a dose of @ mg every @ weeks , with interferon beta-@a , administered intramuscularly at a dose of @ g once weekly , for up to @ weeks .